-
Something wrong with this record ?
Lithium rescues cultured rat metatarsals from dexamethasone-induced growth failure
O. Soucek, O. Cinek, L. Velentza, V. Semjonov, M. Bezdicka, F. Zaman, L. Sävendahl
Language English Country United States
Document type Journal Article
NLK
Free Medical Journals
from 1967 to 1 year ago
ProQuest Central
from 2016-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2016-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2016-01-01 to 1 year ago
- MeSH
- beta Catenin * metabolism MeSH
- Lithium Chloride * pharmacology MeSH
- Dexamethasone * pharmacology MeSH
- Glucocorticoids pharmacology MeSH
- Rats MeSH
- Humans MeSH
- Metatarsal Bones * drug effects MeSH
- Rats, Sprague-Dawley MeSH
- Cell Proliferation drug effects MeSH
- Growth Plate drug effects metabolism MeSH
- Wnt Signaling Pathway drug effects MeSH
- Bone Development drug effects MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Glucocorticoids are commonly used in children with different chronic diseases. Growth failure represents a so far untreatable undesired side-effect. As lithium chloride (LiCl) is known to induce cell renewal in various tissues, we hypothesized that LiCl may prevent glucocorticoid-induced growth failure. METHODS: We monitored growth of fetal rat metatarsals cultured ex-vivo with dexamethasone and/or LiCl, while molecular mechanisms were explored through RNA sequencing by implementing the differential gene expression and gene set analysis. Quantification of β-catenin in human growth plate cartilage cultured with dexamethasone and/or LiCl was added for verification. RESULTS: After 14 days of culture, the length of dexamethasone-treated fetal rat metatarsals increased by 1.4 ± 0.2 mm compared to 2.4 ± 0.3 mm in control bones (p < 0.001). The combination of LiCl and dexamethasone led to bone length increase of 1.9 ± 0.3 mm (p < 0.001 vs. dexamethasone alone). By adding lithium, genes for cell cycle and Wnt/β-catenin, Hedgehog and Notch signaling, were upregulated compared to dexamethasone alone group. CONCLUSIONS: LiCl has the potential to partially rescue from dexamethasone-induced bone growth impairment in an ex vivo model. Transcriptomics identified cell renewal and proliferation as candidates for the underlying mechanisms. Our observations may open up the development of a new treatment strategy for bone growth disorders. IMPACT: LiCl is capable to prevent glucocorticoid-induced growth failure in rat metatarsals in vitro. The accompanying drug-induced transcriptomic changes suggested cell renewal and proliferation as candidate underlying mechanisms. Wnt/beta-catenin pathway could be one of those novel mechanisms.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004141
- 003
- CZ-PrNML
- 005
- 20250206105949.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41390-024-03192-6 $2 doi
- 035 __
- $a (PubMed)38684886
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Soucek, Ondrej $u Vera Vavrova Lab/VIAL, Department of Paediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. ondrej.soucek@lfmotol.cuni.cz $u Paediatric Endocrinology Unit, Department of Children's and Women's Health, Karolinska Institutet, Stockholm, Sweden. ondrej.soucek@lfmotol.cuni.cz
- 245 10
- $a Lithium rescues cultured rat metatarsals from dexamethasone-induced growth failure / $c O. Soucek, O. Cinek, L. Velentza, V. Semjonov, M. Bezdicka, F. Zaman, L. Sävendahl
- 520 9_
- $a BACKGROUND: Glucocorticoids are commonly used in children with different chronic diseases. Growth failure represents a so far untreatable undesired side-effect. As lithium chloride (LiCl) is known to induce cell renewal in various tissues, we hypothesized that LiCl may prevent glucocorticoid-induced growth failure. METHODS: We monitored growth of fetal rat metatarsals cultured ex-vivo with dexamethasone and/or LiCl, while molecular mechanisms were explored through RNA sequencing by implementing the differential gene expression and gene set analysis. Quantification of β-catenin in human growth plate cartilage cultured with dexamethasone and/or LiCl was added for verification. RESULTS: After 14 days of culture, the length of dexamethasone-treated fetal rat metatarsals increased by 1.4 ± 0.2 mm compared to 2.4 ± 0.3 mm in control bones (p < 0.001). The combination of LiCl and dexamethasone led to bone length increase of 1.9 ± 0.3 mm (p < 0.001 vs. dexamethasone alone). By adding lithium, genes for cell cycle and Wnt/β-catenin, Hedgehog and Notch signaling, were upregulated compared to dexamethasone alone group. CONCLUSIONS: LiCl has the potential to partially rescue from dexamethasone-induced bone growth impairment in an ex vivo model. Transcriptomics identified cell renewal and proliferation as candidates for the underlying mechanisms. Our observations may open up the development of a new treatment strategy for bone growth disorders. IMPACT: LiCl is capable to prevent glucocorticoid-induced growth failure in rat metatarsals in vitro. The accompanying drug-induced transcriptomic changes suggested cell renewal and proliferation as candidate underlying mechanisms. Wnt/beta-catenin pathway could be one of those novel mechanisms.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a dexamethason $x farmakologie $7 D003907
- 650 12
- $a chlorid lithný $x farmakologie $7 D018021
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 12
- $a metatarzální kosti $x účinky léků $7 D008682
- 650 12
- $a beta-katenin $x metabolismus $7 D051176
- 650 _2
- $a signální dráha Wnt $x účinky léků $7 D060449
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a růstová ploténka $x účinky léků $x metabolismus $7 D006132
- 650 _2
- $a glukokortikoidy $x farmakologie $7 D005938
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a vývoj kostí $x účinky léků $7 D001846
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Cinek, Ondrej $u Department of Paediatrics and Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Velentza, Lilly $u Paediatric Endocrinology Unit, Department of Children's and Women's Health, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Semjonov, Valerij $u Department of Paediatrics and Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Bezdicka, Martin $u Vera Vavrova Lab/VIAL, Department of Paediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Zaman, Farasat $u Paediatric Endocrinology Unit, Department of Children's and Women's Health, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Sävendahl, Lars $u Paediatric Endocrinology Unit, Department of Children's and Women's Health, Karolinska Institutet, Stockholm, Sweden $u Astrid Lindgren Children ́s Hospital, Karolinska University Hospital, Stockholm, Sweden
- 773 0_
- $w MED00003741 $t Pediatric research $x 1530-0447 $g Roč. 96, č. 4 (2024), s. 952-963
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38684886 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206105945 $b ABA008
- 999 __
- $a ok $b bmc $g 2263722 $s 1240148
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 96 $c 4 $d 952-963 $e 20240429 $i 1530-0447 $m Pediatric research $n Pediatr Res $x MED00003741
- LZP __
- $a Pubmed-20250121